| Role |
Name |
Disclosure |
Details |
| Author | Suzanne R Fanning, DO, Fellow, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation | Nothing to disclose | Details | | Coauthor | Mohamad A Hussein, MD, Director, Myeloma Research Program, Consulting Staff, Department of Medical Oncology and Hematology, Cleveland Clinic Cancer Center, Cleveland Clinic Foundation | Nothing to disclose | Details | | Coauthor | Jaya Juturi, MD, Fellow, Department of Hematology and Oncology, Texas Cancer Associates | Nothing to disclose | Details | | Medical Editor | Karen Seiter, MD, Professor, Department of Internal Medicine, Division of Oncology/Hematology, New York Medical College | Novartis Celgene Schering | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Troy H Guthrie, Jr, MD, Director of Cancer Institute, Baptist Medical Center | Nothing to disclose | Details | | CME Editor | Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems | Nothing to disclose | Details | | Chief Editor | Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Mohamad A Hussein, Coauthor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Jaya DELETEJuturi, Coauthor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Troy H Guthrie, jr, Managing Editor |
The contributor discloses no conflict of interest. |
|